Physician profile

Keith Gage Bennett

Family Medicine · Pine Bluff, AR

NPI 1427085075

$701.20

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$95.61

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Smith+Nephew, INC. $395.76 2021-2024 Collagenase Santyl, Pico 7
Convatec INC. $90.45 2022-2023
Abbvie INC. $52.13 2021-2022
Paratek Pharmaceuticals, INC. $46.11 2022
Acera Surgical, INC. $29.49 2021-2022
Solventum Corporation $21.17 2024 Activ.A.C.
Aroa Biosurgery Incorporated $20.14 2022
Boston Scientific Corporation $17.83 2021
Bioventus LLC $14.24 2022
Kci USA, INC. $13.88 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Keith Gage Bennett

$701.20

in general payments reported 2019-2025

Years
2021-2024
Top company
Smith+Nephew, INC.

https://glasscript.com/doctor/200903/keith-gage-bennett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.